Skip to main content
L

Lionco Pharmaceutical Group Co.,Ltd. — Investor Relations & Filings

Ticker · 603669 ISIN · CNE1000022R8 LEI · 300300EU7LBPZ25TZO93 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 1,201 across all filing types
Latest filing 2025-04-18 Board/Management Inform…
Country CN China
Listing Shanghai Stock Exchange 603669

About Lionco Pharmaceutical Group Co.,Ltd.

Lionco Pharmaceutical Group Co., Ltd. is a pharmaceutical enterprise focused on the research, development, production, and sale of chemical drug preparations. The company specializes in a diverse range of therapeutic areas, including anti-infectives, digestive system treatments, cardiovascular health, and respiratory medicine. Its product portfolio primarily consists of high-end generic drugs, featuring formulations such as freeze-dried powder for injection, small-volume injections, and solid oral dosages. Lionco emphasizes technological innovation and quality control to provide clinical solutions for various medical conditions. The group operates multiple manufacturing facilities and maintains a comprehensive distribution network to serve healthcare providers and patients.

Recent filings

Filing Released Lang Actions
关于公司副总经理退休离职的公告
Board/Management Information Classification · 100% confidence The document is an announcement regarding the retirement and resignation of the company's vice general manager due to reaching the statutory retirement age. It discusses management changes and does not contain financial data, audit information, or regulatory filings. The content fits the category of Board/Management Information, as it announces a change in senior management personnel.
2025-04-18 Chinese
募集资金管理制度（2025年4月修订）
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the internal rules and procedures for managing and using funds raised by the company through securities issuance. It references relevant Chinese laws and stock exchange regulations, outlines the responsibilities of the board, management, sponsors, and auditors in overseeing the use of raised funds, and specifies reporting and disclosure requirements. The document is a policy or governance document related to capital management rather than a financial report, earnings release, or announcement. It does not contain financial statements or results but rather internal control and governance rules for fundraising capital. Therefore, it fits best under Governance Information (CGR), which covers reports detailing the company's internal rules and governance practices related to capital management.
2025-04-18 Chinese
关于募集资金年度存放与使用情况的专项报告
Capital/Financing Update Classification · 95% confidence The document is a detailed report on the annual storage and usage of raised funds by Lingkang Pharmaceutical Group Co., Ltd. It includes specifics on the amounts raised through stock issuance and convertible bonds, the management and use of these funds, project investment details, changes in project funding, and compliance with regulatory requirements. The document references specific approvals by the China Securities Regulatory Commission, detailed financial figures, and audit verification reports. It is not a general annual report or earnings release but a specialized report focused on the use of raised capital. This matches the definition of a Capital/Financing Update (CAP), which covers updates on company fundraising and capital structure changes. The document length and content confirm it is the report itself, not just an announcement. Therefore, the correct classification is CAP with high confidence.
2025-04-18 Chinese
灵康药业集团股份有限公司内部控制审计报告
Regulatory Filings
2025-04-18 Chinese
关于灵康药业集团股份有限公司募集资金存放与实际使用情况的鉴证报告
Regulatory Filings
2025-04-18 Chinese
关于灵康药业集团股份有限公司2024年度营业收入扣除情况表的专项核查报告
Regulatory Filings
2025-04-18 Chinese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.